Skip to main content
Deciphera
Deciphera
  • Patients & Caregivers
  • Healthcare Professionals
  • Clinical Studies
  • Presentations & Publications
  • News
twitter linkedin
  • Discovery Platform
  • Pipeline
    • Ripretinib
    • Vimseltinib
    • DCC-3116
    • DCC-3084
    • DCC-3009
    • Preclinical Pipeline
    • Expanded Access
  • Our Medicine
  • About
    • Management
  • Join Us
    • Open Positions
  • Discovery Platform
  • Pipeline
    • Ripretinib
    • Vimseltinib
    • DCC-3116
    • DCC-3084
    • DCC-3009
    • Preclinical Pipeline
    • Expanded Access
  • Our Medicine
  • About
    • Management
  • Join Us
    • Open Positions
  • Patients & Caregivers
  • Healthcare Professionals
  • Clinical Studies
  • Presentations & Publications
  • News
twitter linkedin
October 29 2019
DCC-3116
AACR-NCI-EORTC

Preclinical studies with DCC-3116, an ULK kinase inhibitor designed to inhibit autophagy as a potential strategy to address mutant RAS cancers. 

Pagination

  • Previous page ‹‹
  • You're on Page 2
Subscribe to DCC-3116
Deciphera
twitter linkedin
contact us
  • Discovery Platform
  • Pipeline
    • Ripretinib
    • Vimseltinib
    • DCC-3116
    • DCC-3084
    • DCC-3009
    • Preclinical Pipeline
    • Expanded Access
  • Our Medicine
  • About
    • Management
  • Join Us
    • Open Positions
  • Contact Us
  • Terms of Use
  • Privacy Policy
  • Recruiting Privacy Policy
  • Web Accessibility Statement

© 2025 Deciphera Pharmaceuticals, LLC. The following are registered trademarks of Deciphera Pharmaceuticals, LLC: QINLOCK, the QINLOCK logo, DECIPHERA, and the Deciphera logo. The following are trademarks of Deciphera Pharmaceuticals, LLC: ROMVIMZA and the ROMVIMZA logo.

Back to top